Viewpoints » Visby Medical to Present Poster at the Julius Schacter Chlamydia Conference

06/16/2022 • Viewpoint

Visby Medical to Present Poster at the Julius Schacter Chlamydia Conference

Julius Schachter Fifteenth International Symposium on Human Chlamydial Infections

June 19-June 24, 2022

The Historic Menger Hotel
204 Alamo Plaza
San Antonio,TX 78205

Offering a high-quality scientific meeting covering all aspects in the field of chlamydia research, this symposium provides an excellent opportunity for specialists and trainees in sexual health, HIV medicine, public health, microbiology, epidemiology and behavioral science to share their ideas and experiences. Participants will be able to discuss the latest advances and progress in the field from the varied viewpoints of clinical practice and research in chlamydial biology, laboratory detection, public health epidemiology, and sexual behavior.

Teresa Abraham will be presenting in a Tuesday evening poster session.

Learn more about the Visby Medical Sexual Health Test

04/05/2024 • Viewpoint

The Case for PCR at the Point of Care: Reshaping STI Testing in Urgent Care Clinics

In light of the rising rates of sexually transmitted infections (STIs), urgent care clinics have found themselves at a crucial crossroads. PCR (Polymerase Chain Reaction) testing at the point of care emerges as a potential game-changer.

03/14/2024 • Viewpoint

Understanding the Financial Impact of PCR Point of Care Testing for STIs

The adoption of point-of-care polymerase chain reaction (PCR) testing represents a significant leap forward in diagnostic capabilities. With its promise of speed, accuracy, and efficiency, PCR testing technology is setting a new standard in patient care.

03/07/2024 • Viewpoint

5 Frequently Asked Questions on Implementing PCR into Urgent Care

02/21/2024 • Press Release

CARB-X awards funding to Visby Medical for gonorrhea, antibiotic susceptibility test

The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced today that it will award biotechnology company Visby Medical of San Jose, California, up to $1.8 million to develop a portable polymerase chain reaction (PCR) test that can detect gonorrhea and assess its susceptibility to ciprofloxacin.